journal article·2025-12-19

Fe-MoS 2 Nanozymes Combined with Antagonistic Bacteria for the Inhibition of Agrobacterium tumefaciens Growth and Biofilm Formation

Chunxiao Li, Jitao Li, Chao Li, Yini Xu, Qi Liu, Yaling Yang, Yuzhu Song

ACS Applied Nano Materials· Volume 8· Issue 50
Publisher page

Abstract

Agrobacterium tumefaciens ( A. tumefaciens ) underlies the pathogenesis of crown gall disease and is characterized by tumor-like gall formation on the stems and roots of a wide variety of economically important plant species. It is necessary to explore anti- A. tumefaciens agents due to the limited availability of current treatments. In this study, Fe,S-decorated polyoxometalate-based molybdenum disulfide nanosheet (Fe-MoS 2 NS) nanozymes were designed and synthesized to efficiently act against A. tumefaciens . Based on antagonistic bacteria (AT-11) from soil with a high infection rate of A. tumefaciens, the isolated strain presents anti- A. tumefaciens property, and Fe-MoS 2 -bound AT-11 exhibited excellent peroxidase (POD)-like activity for specifically inhibiting the growth and biofilm formation of A. tumefaciens . In addition, electron transfer between Fe 2+ /Fe 3+ and Mo 4+ /Mo 6+ provided more active sites, further increasing the POD-like catalytic activity based on Fenton-like mechanisms, amplifying the chemodynamic therapy potential. Compared to MoS 2, Fe-MoS 2 exhibited a 37.1-fold increase in the POD-like catalytic activity. Fe-MoS 2 combined with AT-11 demonstrated a remarkable synergistic effect against A. tumefaciens with a minimum fungicidal concentration value of 15 μg/mL and significantly reduced the biofilm formation with 15 μg/mL concentration while preserving AT-11 species. The research results indicated that A. tumefaciens inactivation began with membrane rupture, followed by the oxidation and leakage of intracellular substances. Moreover, Fe-MoS 2 inhibits tumor formation on the tomato stem when treatments were applied after A. tumefaciens infection to wounded tissues. This study demonstrated that Fe-MoS 2 can serve as an effective and economical bactericide for an efficient biocontrol of crown gall disease with good biocompatibility and low cost.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Advanced Photocatalysis Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Life Science and Technology

Kunming University of Science and Technology

References (47)

Show source-provided references
1. 10.1007/978-0-387-72290-0_110.1007/978-0-387-72290-0_1 ↗
2. 10.1080/13102818.2020.185872210.1080/13102818.2020.1858722 ↗
3. 10.1073/pnas.060036610310.1073/pnas.0600366103 ↗
4. 10.1351/PAC-CON-08-07-0310.1351/PAC-CON-08-07-03 ↗
5. 10.1094/PDIS-94-8-1064C10.1094/PDIS-94-8-1064C ↗
6. 10.1007/82_2018_8510.1007/82_2018_85 ↗
7. 10.1007/s42161-018-00211-410.1007/s42161-018-00211-4 ↗
8. 10.1007/s13313-020-00682-z10.1007/s13313-020-00682-z ↗
9. 10.1079/9781845934927.000110.1079/9781845934927.0001 ↗
10. 10.3389/fpls.2014.0017610.3389/fpls.2014.00176 ↗
11. 10.1016/j.pestbp.2020.02.01210.1016/j.pestbp.2020.02.012 ↗
12. 10.2478/v10045-012-0075-710.2478/v10045-012-0075-7 ↗
13. 10.1079/9781845930257.000010.1079/9781845930257.0000 ↗
14. 10.3389/fmicb.2019.0289410.3389/fmicb.2019.02894 ↗
15. 10.1016/j.jcis.2023.10.05010.1016/j.jcis.2023.10.050 ↗
16. 10.1002/adfm.20250443410.1002/adfm.202504434 ↗
17. 10.1016/j.snb.2024.13622610.1016/j.snb.2024.136226 ↗
18. 10.1007/s11426-024-2592-410.1007/s11426-024-2592-4 ↗
19. 10.1002/anie.20070454610.1002/anie.200704546 ↗
20. 10.1039/c2cs35292c10.1039/c2cs35292c ↗
21. 10.1126/science.118537210.1126/science.1185372 ↗
22. 10.1016/j.nanoms.2024.03.00210.1016/j.nanoms.2024.03.002 ↗
23. 10.1002/anie.20231503110.1002/anie.202315031 ↗
24. 10.1039/C8TB01853G10.1039/C8TB01853G ↗
25. 10.1039/D3NA00210A10.1039/D3NA00210A ↗
26. 10.1002/anie.20211617010.1002/anie.202116170 ↗
27. 10.1039/c2cs35145e10.1039/c2cs35145e ↗
28. 10.1002/anie.20070434410.1002/anie.200704344 ↗
29. 10.1021/acsami.2c1124510.1021/acsami.2c11245 ↗
30. 10.1016/j.apsusc.2022.15249610.1016/j.apsusc.2022.152496 ↗
31. 10.1039/C7TB02676E10.1039/C7TB02676E ↗
32. 10.1016/j.cclet.2022.10810910.1016/j.cclet.2022.108109 ↗
33. 10.1016/j.cej.2022.13451110.1016/j.cej.2022.134511 ↗
34. 10.1016/j.seppur.2021.11920010.1016/j.seppur.2021.119200 ↗
35. 10.1016/j.jconrel.2022.05.04710.1016/j.jconrel.2022.05.047 ↗
36. 10.1002/adhm.20220036010.1002/adhm.202200360 ↗
37. 10.1016/j.seppur.2023.12399710.1016/j.seppur.2023.123997 ↗
38. 10.1002/adma.20210063710.1002/adma.202100637 ↗
39. 10.1021/acs.nanolett.5b0038810.1021/acs.nanolett.5b00388 ↗
40. 10.1021/acsami.0c0178910.1021/acsami.0c01789 ↗
41. 10.1038/srep1742210.1038/srep17422 ↗
42. 10.1016/j.apcata.2019.02.00510.1016/j.apcata.2019.02.005 ↗
43. 10.1016/j.cej.2020.12798710.1016/j.cej.2020.127987 ↗
44. 10.1038/ncomms1067210.1038/ncomms10672 ↗
45. 10.1021/acs.accounts.8b0001110.1021/acs.accounts.8b00011 ↗
46. 10.1016/j.bioactmat.2021.10.02310.1016/j.bioactmat.2021.10.023 ↗
47. 10.1016/j.jcis.2023.04.14910.1016/j.jcis.2023.04.149 ↗